Bald men at higher risk of having severe coronavirus, shocking new research suggests – Express

Researchers believe the link is so strong that they have called for baldness to be listed as a risk factor called the Gabrin sign This is after Dr Frank Gabrin, the first US physician to die of coronavirus, who was also bald. Lead author of the study, Professor Carlos Wambier of Brown University, told The Telegraph: "We really think that baldness is a perfect predictor of severity."

Recently scientists have hypothesised that coronavirus is more deadlier for men due than women because of testosterone.

Italian doctors have previously found patients given androgen deprivation therapy, which radically cuts testosterone levels, were four times less likely to die from coronavirus.

A protein, TMPRSS2, is driven up by testosterone and scientists think the virus could use this protein to help it unlock cells.

Researchers at Londons Institute for Cancer Research are examining the link further, whilst the University of California, Los Angeles is looking at testosterone-blocking therapy to help with coronavirus treatment.

Testosterone can produce dihydrotestosterone (DHT) which can lead to hair loss.

Though as per South China Morning Post, it is possible to have low levels of testosterone but high levels of DHT.

The further data on baldness further raises the possibility that treatments that cut testosterone could be used to slow the virus down.

Discussions have taken place about a trial using baldness drugs to treat coronavirus.

READ MORE:Chinas Xi Jinping vows to strengthen public health system

A study of 122 patients in three Madrid hospitals found 79 percent of the men were bald.

Howard Soule, executive vice president at the Prostate Cancer Foundation, told Science Magazine: "Everybody is chasing a link between androgens and the outcome of Covid-19.

Karen Stalbow, Head of Policy at Prostate Cancer UK, said: There have been several recent pieces of research which indicate there may be a link between male hormones and increased risk of Covid-19.

This has led some researchers to investigate whether hormone therapies commonly used to treat prostate cancer, such as enzalutamide, could reduce this risk.

DON'T MISS

New Yorks coronavirus came from Europe and NOT China (LATEST)Antimalarial drug study withdrawn as authors deny its authenticity (ANALYSIS)Vaccine summit in UK exceeds target by raising nearly 7 billion(NEWS)

However, most of the research so far has been in the lab, and there is conflicting evidence over whether the hormone therapies have the same impact in the lungs as they would in prostate cells.

There are now several clinical studies starting which hope to address these issues, but much more evidence is needed before we can know whether these hormone therapies would be an effective treatment for Covid-19.

Professor Nick James of the Institute for Cancer Research has warned against using testosterone cutting treatment as a preventive measure due to their severe side effects.

He explained to the Mail on Sunday: Being on these drugs is the male equivalent of going through the menopause.

You would almost certainly cause more harm than good.

According to the NHS, the following people are considered clinically extremely vulnerable: people who have had an organ transplant, people undergoing chemotherapy or antibody treatment for cancer, intense radiotherapy, cancer treatments which affect the immune system, people who have blood or bone marrow cancer, those have had a bone marrow or stem cell transplant in the previous six months, or are still taking immunosuppressant medicine, those with a severe lung condition, those with a condition which puts them at high risk of infection or taking medicines which makes them more likely to do so and expecting mothers with heart conditions.

The list of people are considered at moderate risk includes: Those over 70, expecting mothers, those who have lung conditions which are not severe, those with heart disease, diabetics, those with chronic kidney disease, those with liver disease, those with a condition affecting the brain or nerves and those who are obese.

Previously, environmental factors were hypothesised as being behind the higher risk to men.

This includes the fact men are more likely to be smokers.

Read more from the original source:
Bald men at higher risk of having severe coronavirus, shocking new research suggests - Express

Covid19: Increase in centers moving to collect convalescent plasma is creating a new demand says Chetan Mak.. – ETHealthworld.com

By Smridhi Uppal

In an interaction with EThealthworld, Mr. Chetan Makam, Managing Director, Terumo Penpol Pvt. Ltd talks about how Covid19 has affected the essentials industry in carrying out new normals with respect to terms of supply and demand.

How has the covid-19 pandemic impacted the healthcare sector?The healthcare sector has various segments; delivery of patient care, medical devices, pharma etc. and each of them has been affected in different ways.

TerumoBCT specializes in the manufacturing of medical equipment, particularly equipments used in blood and cell collections. The need for blood never diminishes as patients need blood and blood components for a variety of treatments such as oncology, sickle cell disease, maternal and child health related intervention and for emergency surgeries.

In India, ICMR has initiated a multi-center clinical trial, titled A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. (PLACID Trial). About 35 centers across India are approved for the trials and we are supporting several of them.

What are the major investments that TerumoBCT is continuing to make?

We at Terumo Penpol conduct a couple of hundred blood donation drives and promote voluntary blood donation (VBD). Our CSR activities include support for various organizations working in Thalassemia, Hemophilia as well as in stem cell donations.

Terumo is an established company in Kerala. We continue to invest both in the well-being of our associates and in high quality medical devices that support the demands of the local market and in fact, the world. The reliability of the local supply chain, products from our facility make their way around the globe to meet essential healthcare needs.

Terumo Penpol was the first medtech company chosen to participate in the Japan-India Institute of Manufacturing (JIM) program. Overseen by the Japanese Ministry of Economy, Trade and Industry, JIM was borne out of PM Narendra Modis request to his Japanese counterpart Shinzo Abe for support to scale up industrial work skills among Indian youth. Our participation contributes to the Skill India, Make in India and Ayushman Bharat initiatives.

We have invested over the past few years in a comprehensive and established Business Continuity Policy, designed to safeguard associates around the world and ability to deliver products worldwide. Guided by this policy and social responsibility to healthcare, we are committed to providing continuous support to customers so they can continue their business operations during critical events as they rely on the quality of products and the services we provide.

How has your company contributed to combating this pandemic?We continue to operate our factories and provide products and services to our customers globally as they depend on us to collect blood, cells and now plasma, while ensuring that our employees are working in safe conditions.Our parent company, Terumo Corporation, has donated USD 2.4 million in cash and products to support COVID-19 relief efforts worldwide including a USD 1 million donation to the COVID-19 Solidarity Response Fund for WHO. The Solidarity Response Fund supports research and development of new therapies and vaccines, global response to the pandemic, such as tests and personal protective equipment, and education and communication efforts to protect individuals against the infection.

Terumo BCT specifically, focused on unlocking the potential of blood and cells and to the contributing solutions that can have an impact now to fight against COVID-19. In the current context, our products are uniquely placed to cater to various medical interventions. We have a product for convalescent plasma collection, which provides passive immunity to patients with COVID-19 and may help preventing infection in high risk groups, such as healthcare workers. Our Pathogen Reduction Technology system is already being used in many countries to add a layer of safety in blood transfusion and recently for convalescent plasma.

Similarly, we have also a product to help treat respiratory failure in adult patients with confirmed COVID-19. The treatment reduces pro-inflammatory cytokine levels, which cause cytokine storm. The cytokine storm that occurs in some COVID-19 patients, leads to severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death.

What are your expectations from the government?The local government in Thiruvananthapuram, Kerala has provided us with the permissions to operate as an essential industry. Given the treatments and technologies that we can bring to serve more patients, having a process with the regulators to provide emergency use authorization would be a plus. Expedited approvals for products made at multiple locations to ensure business continuity. Relief on import duties on products for the duration of the COVID restrictions to offset the cost of increased freight. Governments can also help by paying outstanding dues immediately.

How do you think this crisis will affect the balance sheets of firms?The key for many companies will be to devise ways to conserve cash as it will allow them to be flexible and respond better to the changing scenarios. its the time to reduce 1 percent from the CSR activities and conserve money for investing tomorrow, by authorizing 2 percent from it.

What are the challenges do you see in Make in India? I am glad to see that the Government of India is bringing in policies to make India a manufacturing hub for medical devices. What is encouraging is that the government is emphasizing on the need for the products to be at par with international standards so that it can cater to the domestic as well as overseas markets. This is indeed a progressive outlook and need to be applauded. One area which needs to be addressed is absence of skilled labour to support domestic/local manufacturing of medical devices.

Hence skilling of labour force is necessary. Another area where there has been a lacuna in most cases is absence of collaborative approach wherein government, private sector and academia join forces for better outcome. However, in the fight against COVID- 19, Indias mitigation response has seen collaborative research and innovation.

Indian Government, academia, and the private sector have come together to bring in pioneering solution. Following this triple helix approach even in the long-term (post-COVID) would benefit the medical device players as well as the customers as it brings together capabilities and resources to solve common problems more efficiently. For the government, it helps address healthcare challenges through innovative and cost-effective approaches.

ICMR has initiated a multi-center clinical trial, titled A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. (PLACID Trial). About 35 centers across India are approved for the trials and we are supporting several of them. Hence, it is important to take forward this very important learning from the pandemic and MNCs and local manufacturers should work in tandem to bring in effective solutions to address healthcare challenges in India and globally.

Tell us something about the latest developments and global trends in medical devices associated with blood industry? Spectra Optia apheresis system has seen interesting developments recently. In Covid-19 patients, it aims reduce the number of cytokines and other inflammatory blood proteins that control a cells immune response, filtering the blood and returning it to the patient. The proteins that are removed are typically elevated during infections and can be associated with a cytokine storm that occurs in some COVID-19 patients, leading to severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death.

Another interesting development has been that researchers have established that exposing the novel coronavirus to the vitamin riboflavin and ultraviolet light decreases the viral count in human plasma and whole-blood products, a development that may help lower the possibility of transmission of the virus via blood transfusion. The scientists from Colorado State University (CSU) in the US, has still not been able to decipher if SARS-CoV-2 could be transmitted by blood transfusion. However, it is an interesting development to watch for. The device used is the Mirasol Pathogen Reduction Technology System which has been developed by us.

Visit link:
Covid19: Increase in centers moving to collect convalescent plasma is creating a new demand says Chetan Mak.. - ETHealthworld.com

The latest on the coronavirus outbreak for June 5 – CBC.ca

Unmasking the stealth virus behind COVID-19

Scientists have discovered the pandemic-causing coronavirus is unique in short-circuiting the safest way our immune system kills off a virus which could have implications for using interferon to treat COVID-19, writes CBC's Amina Zafar. Interferon describes a family of proteins produced by the body's immune system in response to an invading viral infection. As the name implies, interferon interferes with the virus's ability to copy itself. Interferon drugs are made in the lab and were used for years to treat hepatitis, a liver infection, as well as other diseases that involve the immune system, such as multiple sclerosis and some cancers.

In May, researchers in Hong Kong published the results of their Phase 2 trial on fewer than 150 people who were admitted to hospital with mild or moderate COVID-19. Participants were randomly assigned to a combination of potential antivirals, including interferon, or placebo injections for two weeks. The findings lent support to the idea of continuing research efforts, including in Canada, to investigate interferon in larger, blinded trials designed to find more definitive answers. Dr. Jordan Feld, a liver specialist at Toronto General Hospital and senior scientist at U of T, previously used interferon to treat people infected with hepatitis. He's now leading a Phase 2 clinical trial to test a targeted form of the drug, called peginterferon lambda, in injections compared with saline placebo injections. "It's kind of like a stealth virus," Feld said of SARS-CoV-2, the virus that causes COVID-19.

Normally, when interferon in the body's white blood cells responds to a viral invader, the interferon sends out a flare signal so nearby cells will work to stop the virus from copying itself or replicating if they, too, should be invaded. In ferrets infected in the lab (a common animal model for studying respiratory viruses), healthy human lung cells and in people with COVID-19, doctors and scientists say it seems like the natural interferon "flies under the radar" of the immune system and isn't activated the way it should be. Feld said the idea behind giving interferon medications is to provide the body with what it should be making to fend off the infection.

The potential therapeutic approach gained scientific backing last month when a study published in the journal Cell showed a "striking" feature of SARS-CoV-2 infection. Ben tenOever is a Canadian-born professor of microbiology at the Icahn School of Medicine at Mount Sinai in New York who led the Cell study and has been flooded with email requests from researchers the world over to test experimental drug compounds against the virus. He said every cell that gets infected has two major jobs:

Most viruses block both of those roles, and what makes SARS-Cov-2 unique is it blocks the call-to-arms function from interferon only. "Treatment with interferon or drugs that induce interferon, the main character in the call to arms, is probably beneficial," tenOever said. "The secret is to do it early," he said, when people have a mild cough and test positive for the virus and haven't developed respiratory distress.

But there could also be mild side-effects. When we're fighting off a flu virus, blame interferon for feeling so crummy, feverish and achy as your immune system kicks into high gear. Likewise, interferon drugs could also lead to flu-like symptoms for a day or two. Individuals enrolling in COVID-19 clinical trials of interferon will need to weigh whether that (potential) shortfall is worth the (potential) payoff of protection from the deadly damage and delivers key answers that only their participation can offer. Matthew Miller, an associate professor of infectious disease and immunology at McMaster University who isn't involved in the clinical trials or studies, called tenOever's paper "an important first step in understanding how our body is responding to this particular new virus."

Click below to watch more from The National

Ontario considering Stage 2 of reopening despite steady stream of new COVID-19 cases

Ontario Premier Doug Ford signalled that he could announce the next phase of loosening Ontario's pandemic restrictions as early as next week, despite a recent uptick in new cases of COVID-19. Stage 2 would allow a wider number of office-based businesses to reopen and expand the maximum size of social gatherings that's currently limited to five. The province's top criteria for further easing its semi-lockdown is a consistent decline over a two- to four-week period in the daily number of new cases.

That benchmark has not declined consistently in the three weeks since May 14, when Ford announced Ontario's first stage of looser restrictions, including allowing non-essential retail stores outside of shopping malls to open for customers. Since that date, Ontario's daily number of reported new cases dipped below 300 only twice; the daily average in that period has been 371, while the average number of new cases daily has trended upward for the past week. By contrast, Quebec's daily number of new cases has steadily declined since early May and has been below 300 for each of the past four days, while British Columbia has not reported more than 30 cases in a single day since May 6. Fifteen of Ontario's 34 public health units have five or fewer active confirmed cases, according to the provincial COVID-19 database on Thursday. None of the public health units north of the Muskoka region has more than three active cases.

Ontario Health Minister Christine Elliott sounded less bullish than the premier about the prospect of a move to loosen restrictions. Elliott said Thursday that the daily count of new cases has "gone back and forth" in the past week to 10 days. "The numbers are gradually going down. We're going to need to see that to continue," she said. There were some positive trends in Ontario's data reported by the provincial Health Ministry including a steady decline in hospitalizations and a decreasing number of long-term care homes with outbreaks but the province's top public health officials have indicated that it's essential they see a steady reduction in the number of new cases daily before recommending a move to Stage 2. A look at the case numbers by their "episode date" (the estimated date of infection, according to the Public Health Ontario interactive data page) shows no sign of a downward trend through the end of May.

Read more about what's happening in Ontario

Federal government to provide $14B to provinces, territories to 'safely' restart economies

The federal government is providing $14 billion to the provinces and territories to help them "safely and carefully" reopen their economies. Prime Minister Justin Trudeau said the money will help pay for more personal protective equipment (PPE) for front-line health-care workers and businesses, and for child care so that parents can go back to work. "Provinces and territories are facing different realities, so flexibility will be important, but here's the bottom line: For seniors and people who need extra support, for kids and workers this plan is here for you," Trudeau said.

Some of the money going to provinces and territories is meant to help them improve the state of long-term care, and to help municipalities continue providing core public services such as transit. The government is saying little at this point about how the money will be carved up and when it will flow. Ontario Premier Doug Ford said it's a "start" but $14 billion falls far short of what's required to address the "massive need" in Canada's most populous province. "The reality is, we have a $23-billion problem in Ontario, and $14 billion for all of Canada ... just won't cut it," he said. Deputy Prime Minister Chrystia Freeland said the government is taking a collaborative approach to fine-tuning the proposal, and stressed that the federal funds are meant to help with the first six to eight months of economic recovery.

Trudeau also announced that Canadians with disabilities will receive a one-time payment of up to $600 to help offset the higher costs of living during the pandemic. The government has announced emergency aid for unemployed Canadians, students, businesses and seniors, but advocates say that people with disabilities were falling through the cracks. Many face increases in the cost of living, such as higher grocery bills and delivery service fees. Conservative MP Dan Albas, his party's critic for employment, workforce development and disability inclusion, said the federal assistance programs announced to date have come with few details and delays in implementation.

Read more about the support for provinces and territories

Canada added 290,000 jobs in May, but unemployment rate inches up to record high

After losing more than three million jobs in March and April, Canada's economy added 290,000 jobs in May, Statistics Canada reported Friday. The data agency reported that 290,000 more people had paid employment in May than in April. The surge means May was the best one-month gain for jobs in Canada in 45 years, although it happened from an admittedly low bar. It also means the economy has now replaced about 10 per cent of the jobs it lost to COVID-19.

The job gains came as a pleasant surprise to economists, most of whom were expecting more job losses for the month. "We are just beginning to dig out of a massively deep hole, and this will take an extended period of time before the rest of the three million job losses can be recouped," Bank of Montreal's Doug Porter said. Despite the gains, Canada's official unemployment rate rose to 13.7 per cent, as 491,000 more people were looking for work in the job market notably students, whose search for summer work isn't normally recorded in the months before May. Porter noted that at 13.7 per cent, Canada's jobless rate is at its highest point since the Second World War. And "that leaves Canada with the dubious distinction of having the highest unemployment rate among all major economies," he said.

The numbers also showed that two-thirds of the new jobs went to men, while women are still bearing the brunt of the impact from COVID-19. That's partly because men are overrepresented in industries like manufacturing and construction, which are recovering faster than other parts of the economy. "As more COVID-19 restrictions are eased in the coming months, labour market outcomes of men and women with children will continue to be monitored," Statistics Canada said. Hassan Yussuff, president of the Canadian Labour Congress, said the data reveals that "women, low-paid workers and racialized workers continue to struggle disproportionately." "Today's numbers also underscore the desperate need for accelerated action on child care to strengthen the job and economic recovery for women," he said.

Read more about Canada's economic situation

Experts say reaching emissions goals and reopening economies amid pandemic shouldn't be mutually exclusive

A recent study published in Nature Climate Change suggests that as a result of global shutdowns because of the COVID-19 pandemic, CO2 emissions in 2020 could drop by roughly seven per cent. The United Nations Environment Program's report from last November found that in order to limit global warming to 1.5 C above pre-industrial levels, CO2 emissions would need to drop by 7.6 per cent annually over the next decade.

At first glance, it might appear as though a devastating economic shutdown is the only way to reach emissions targets set by the UN. But some experts say this isn't the case, and insist there is a way to have economic growth and reduce emissions that adhere to the UN guidelines. "We can't have this [kind of a shutdown] for tackling climate change absolutely not," said Corinne Le Qur, a Canadian professor of climate change science at the University of East Anglia and lead author of the Nature study. "This is a really painful way to get a decrease in emissions." She also noted that it likely won't last, but said this could be an opportunity to funnel money into green technologies as many governments around the world are trying to stimulate their economies during the pandemic.

Don Drummond, an economist who worked for the federal Department of Finance for 23 years, pointed out that emissions in Canada have almost flat-lined, on average, over the past few years during a period of economic growth (prior to the coronavirus pandemic). This, he said, is evidence that reducing emissions to UN guidelines is possible. "We've achieved higher growth with flattening emissions and we can and should go further and achieve positive growth with declining emissions," said Drummond, an adjunct professor at Queen's University and former chief economist at the Toronto-Dominion Bank. Drummond, who was one of the architects of the goods and services tax in 1991, said there is a long history in Canada of scare-mongering that a given new policy will kill the economy, from the GST to the North American Free Trade Agreement. Quite often, it doesn't, he said.

Donation bins begin to reopen in Nova Scotia with easing of COVID-19 restrictions

Donation bins for some organizations in Nova Scotia, including the IWK Foundation and Big Brothers Big Sisters, are reopening as some restrictions around COVID-19 are being lifted in the province https://www.cbc.ca/news/canada/nova-scotia/n-s-reports-no-new-covid-19-cases-1.5600049. "We're doing a very slow return to service," said Shelda Cochrane, a manager with Big Brothers Big Sisters of Greater Halifax. "We just opened up our bins last weekend and we're really just starting to get that message out to the public."

Big Brothers Big Sisters has taken the tape off bins and put up some new signs asking people to take precautions when they place items in the bins. Donated items are sold to Value Village. "We know people have been spring cleaning and holding on to things and they're anxious to get rid of them. But we also want people to be careful when donating," The donations make up about one-third of its annual budget, after expenses, Cochrane said.

The IWK Foundation, seeking used clothing and footwear, reopened its bins this week. The foundation has 600 bins in Nova Scotia and New Brunswick. A third-party organization based in Digby County, N.S., collects items from the bins and resells them. A portion of the proceeds from the bins benefits the IWK Foundation each year, and the donation bin funds will still go toward the cost of programs, new equipment and research at the children's hospital.

Read the full story about the donation bins

Send us your questions

Still looking for more information on the outbreak? Read more about COVID-19's impact on life in Canada, or reach out to us at covid@cbc.ca.

If you have symptoms of the illness caused by the coronavirus, here's what to do in your part of the country.

For full coverage of how your province or territory is responding to COVID-19, visit your local CBC News site.

To get this newsletter daily as an email,subscribe here.

Click below to watch CBC News Network live

More here:
The latest on the coronavirus outbreak for June 5 - CBC.ca

Participation of Somatic Stem Cells, Labeled by a Unique …

A monoclonal antibody (A3) was generated by using rat malignant fibrous histiocytoma (MFH) cells as the antigen. Generally, MFH is considered to be a sarcoma derived from undifferentiated mesenchymal cells. Molecular biological analyses using the lysate of rat MFH cells revealed that A3 is a conformation specific antibody recognizing both N-glycan and peptide. A3-labeled cells in bone marrow were regarded as somatic stem cells, because the cells partly coexpressed CD90 and CD105 (both immature mesenchymal markers). In the hair follicle cycle, particularly the anagen, the immature epithelial cells (suprabasal cells) near the bulge and some immature mesenchymal cells in the disassembling dermal papilla and regenerating connective tissue sheath/hair papilla reacted to A3. In the cutaneous wound-healing process, A3-labeled epithelial cells participated in re-epithelialization in the wound bed, and apparently, the labeled cells were derived from the hair bulge; in addition, A3-labeled immature mesenchymal cells in the connective tissue sheath of hair follicles at the wound edge showed the expansion of the A3 immunolabeling. A3-labeled immature epithelial and mesenchymal cells contributed to morphogenesis in the hair cycle and tissue repair after a cutaneous wound. A3 could become a unique antibody to identify somatic stem cells capable of differentiating both epithelial and mesenchymal cells in rat tissues.

Keywords: N-glycan; antibody; cutaneous wound healing; hair follicle cycle; somatic stem cells.

Continued here:
Participation of Somatic Stem Cells, Labeled by a Unique ...

COVID-19 Impact on Global Cell Therapy Industry 2020: Market Trends, Size, Share, Applications, SWOT Analysis by Top Key Players and Forecast Report…

TheGlobal Cell Therapy Marketwas estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Growing aging patient population, the rise in cell therapy transplantations globally, and rising disease awareness drive the growth of the market.

Get Sample Copy of this Report @https://www.orianresearch.com/request-sample/1281174

Cell therapyinvolves the administration of somatic cell preparations for the treatment of diseases or traumatic damages. The objective of this study is to provide long term treatment through a single injection of therapeutic cells.

However, stringent regulatory policies may restrain growth of the market in the forecast period.

The global Cell Therapy Market is primarily segmented based on different type, technique, cell source, technology, end users and region.

On the basis of type, the market is split into:* Allogenic Therapies* Autologous Therapies

On the basis of technique, the market is split into:* Stem Cell Therapy* Cell Vaccine* Adoptive Cell Transfer (ACT)* Fibroblast Cell Therapy* Chondrocyte Cell Therapy* Other Technique

On the basis of cell source, the market is split into:* Bone Marrow* Adipose Tissue* Umbilical Cord Blood-Derived Cells

On the basis of technology, the market is split into:* Viral Vector Technology* Cell Immortalization Technology* Genome Editing Technology

On the basis of end user, the market is split into:* Hospitals & Clinics* Regenerative Medicine Centers* Other End Users

Inquire more or share a question if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/1281174

Moreover, the market is classified based on regions and countries as follows:* North America- U.S., Canada* Europe- U.K., France, Germany, Italy and Rest of Europe* Asia-Pacific- China, Japan, India and Rest of Asia Pacific* South America- Brazil, Mexico and Rest of South America* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players: The key players profiled in the market include:* Kolon TissueGene, Inc.* JCR Pharmaceuticals Co. Ltd.* Osiris Therapeutics, Inc.* Stemedica Cell Technologies, Inc.* Fibrocell Science, Inc.* Vericel Corporation* Pharmicell Co., Ltd* Anterogen.CO.,LTD.* Baxter Healthcare Corporation.* Arteriocyte Medical Systems

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:* Global, regional, country, type, technique, cell source, technology, end users market size and their forecast from 2018-2026* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key product, and unique selling points* Analysis on key players strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors short term and long term strategies* Detailed insights on emerging regions, type, technique, cell source, technology and end users with qualitative and quantitative information and facts

Target Audience:* Cell Therapy Manufactures* Traders, Importers, and Exporters* Raw Material Suppliers and Distributors* Research and Consulting Firms* Government and Research Organizations* Associations and Industry Bodies

Research Methodology:The market is derived through extensive use of secondary, primary, in-house research follows by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data products, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data products.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:* Manufacturers* Suppliers* Distributors* Government Body & Associations* Research Institutes

Get Direct Copy of this Report @https://www.orianresearch.com/checkout/1281174

Table of Content1. Introduction2. Research Methodology3. Executive Summary4. Global Cell Therapy Market Overview4.1. Market Segmentation & Scope4.2. Market Trends4.2.1. Drivers4.2.2. Restraints4.2.3. Opportunities4.2.4. Supply Chain Analysis4.3. Global Cell Therapy Market Porters Five Forces Analysis4.4. Global Cell Therapy Market PESTEL Analysis5. Global Cell Therapy Market, by Type5.1. Global Cell Therapy Market, Size and Forecast, 2015-20265.2. Global Cell Therapy Market, by Allogenic Therapies, 2015-20265.2.1. Key driving factors, trends and opportunities5.2.2. Market size and forecast, 2015-20265.3. Global Cell Therapy Market, by Autologous Therapies, 2015-20265.3.1. Key driving factors, trends and opportunities5.3.2. Market size and forecast, 2015-20266. Global Cell Therapy Market, by Technique6.1. Global Cell Therapy Market, Size and Forecast, 2015-20266.2. Global Cell Therapy Market, by Stem Cell Therapy, 2015-20266.2.1. Key driving factors, trends and opportunities6.2.2. Market size and forecast, 2015-20266.3. Global Cell Therapy Market, by Cell Vaccine, 2015-20266.3.1. Key driving factors, trends and opportunities6.3.2. Market size and forecast, 2015-2026

..Continued

Customization Service of the Report:

Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (832) 380-8827 | UK: +44 0161-818-8027

Email:[emailprotected]

Website: http://www.orianresearch.com/

Read more:
COVID-19 Impact on Global Cell Therapy Industry 2020: Market Trends, Size, Share, Applications, SWOT Analysis by Top Key Players and Forecast Report...

FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure – Herald-Mail Media

BALTIMORE, June 4, 2020 /PRNewswire/ -- Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its lead candidate, EXG34217, was approved on May 23, 2020. EXG34217 is an autologous cell therapy for telomere biology disorders with bone marrow failure.

The FDA's approval allows Elixirgen Therapeutics to proceed with its planned Phase I/II, open label, single center clinical trial to assess the safety and tolerability of EXG34217 at Cincinnati Children's Hospital Medical Center (ClinicalTrials.gov Identifier: NCT04211714). This program's treatment paradigm uses Elixirgen Therapeutics' proprietary ZSCAN4 technology to extend the telomeres of the hematopoietic stem cells of the patients.

About Elixirgen Therapeutics, Inc.Elixirgen Therapeutics, Inc. is a Baltimore-based biotechnology company co-founded by Akihiro Ko and Minoru Ko, MD, PhD, which is focused on curing humanity's ailments through innovations in stem cell biology.The company's experienced team of researchers has a wide variety of specialties, enabling it to use both basic and translational research approaches to developing therapies for genetic diseases and vaccines. For more information visit https://ElixirgenTherapeutics.com

Forward-Looking StatementsThis press release may contain "forward-looking" statements, including statements regarding the effectiveness of EXG34217 to treat telomere biology disorders with bone marrow failure and statements relating to the planned clinical trials of EXG34217. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in drug research and development. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Elixirgen Therapeutics that its plans and objectives regarding EXG34217 will be achieved. Any forward-looking statements in this press release speak only as of the date of this press release, and Elixirgen Therapeutics undertakes no obligation to update or revise the statementsin the future, even if new information becomes available.

Contact:Media RelationsElixirgen Therapeutics, Inc.(443) 869-5420Media@ElixirgenTherapeutics.com

Follow this link:
FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure - Herald-Mail Media

Global and United States Adipose Derived Stem Cell Therapy Market 2020 (Coronavirus (COVID-19) Business Impact and Analysis) | Research Industry – SG…

The report study researched by Research Industry US gives comprehensive knowledge and valuable insights about the Global and United States Adipose Derived Stem Cell Therapy Market. Also, the study attempts to deliver significant and detailed insights into the current market prospect and emerging growth scenarios. The report on the Global and United States Adipose Derived Stem Cell Therapy Market also emphasizes on market players as well as the new entrants in the market landscape.

Global and United States Adipose Derived Stem Cell Therapy Market is estimated to reach $XX billion in 2019 with a CAGR of XX% from 2019 to 2025.

Download Free Sample PDF Report (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Global and United States Adipose Derived Stem Cell Therapy Market @ http://researchindustry.us/report/global-and-united-states-adipose-derived-stem-cell-therapy-market-rie/546467/request-sample

The Global and United States Adipose Derived Stem Cell Therapy Market report is a precise and deep-dive study on the current state that aims at the major drivers, market strategies, and imposing growth of the key players. Worldwide Adipose Derived Stem Cell Therapy Market Industry also offers a granular study of the dynamics, segmentation, revenue, share forecasts, and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Adipose Derived Stem Cell Therapy Market industry.

Impact of Coronavirus (COVID-19) on Global and United States Adipose Derived Stem Cell Therapy Market.

Coronavirus (COVID-19) is spreading across the world with a serious impact on the economy and the global market. The report considers and accounts for the impact of COVID-19 on Global and United States Adipose Derived Stem Cell Therapy Market across all the segments, regions, countries, and key players. North America and Europe are worst-hit countries by Coronavirus which are key players in the global economy. The report provides a detailed analysis of the impact on the market, growth strategies, supply china disruption, consumption pattern of the Global and United States Adipose Derived Stem Cell Therapy Market.

The report provides market size with 2019 as the base year in consideration and a yearly forecast until 2026 in terms of Revenue (USD Million). The estimates for all segments including type and application have been provided on a regional basis for the forecast period mentioned above. We have implemented a mix of top-down and bottom-up approaches for market sizing, analyzing the key regional markets, dynamics, and trends for various applications.

Browse Complete Report Description and Full TOC @ http://researchindustry.us/report/global-and-united-states-adipose-derived-stem-cell-therapy-market-rie/546467

The Global and United States Adipose Derived Stem Cell Therapy Market has been estimated by integrating the regional markets.

By Type:

Cells, Allogeneic Stem Cells, etc.

By Application:

Application, Research Application, etc.

Competitive Landscape:

Key players profile in the report include

Market segment by players, this report coversAlloCureMesoblastCelllerisAntriaIntrexonCelgene CorporationTissue GenesisCytori TherapeuticsCorestemPluristem TherapeuticsCyagenBioRestorative TherapiesLonzaPluristem TherapeuticsCelltex Therapeutics CorporationiXCells Biotechnologies

The report of Global and United States Adipose Derived Stem Cell Therapy Market studies the key players present in the market. The chapter includes the competitive landscape section which provides the full and in-depth analysis of the current market trends, changing technologies, and developments that will be beneficial for the companies, which are competing in the market. The report offers an overview of revenue, demand, and supply of data, futuristic cost, and growth analysis during the projected year. In addition to a brief overview of the company, analysts shed light on their valuation and evolution. It also discusses the list of important products and the ones in the pipeline. The competitive landscape is analyzed by understanding the approaches of the companies and the initiatives they have taken in recent years to triumph over the intensive competition.

A section of the report has given complete information about regional analysis. It provides a market outlook and positions the forecast within the context of the overall Global and United States Adipose Derived Stem Cell Therapy Market. Research Industry US has segmented the Global and United States Adipose Derived Stem Cell Therapy Market into major geographical regions such as North America, Europe, Asia Pacific, South America, and the Middle East and Africa. Potential new entrants desiring to target only high growth areas are also incorporated in this informative section of the Global and United States Adipose Derived Stem Cell Therapy Market.

Request Customization or Discount of This Report @ http://researchindustry.us/report/global-and-united-states-adipose-derived-stem-cell-therapy-market-rie/546467/request-customization

Report Objectives:

Get In Touch!Research IndustryNavale ICON IT Park,Office No. 407, 4th Floor, Mumbai Banglore Highway, Narhe, PuneMaharashtra 411041Phone +1 213-275-4706Emailsales@researchindustry.us

David Barstow is a senior editor at SG Research Sphere covering products, apps, services, and consumer tech issues and trends. He is very active in social media and collects regular information for the company. He brings a great vision to the nexus of content and the social, digital, video and pragmatic network. He has eight years of experience with his expertise in conglomerate industries.

Go here to read the rest:
Global and United States Adipose Derived Stem Cell Therapy Market 2020 (Coronavirus (COVID-19) Business Impact and Analysis) | Research Industry - SG...

MSC Therapy for Acute Respiratory Distress Syndrome; It’s Time to Accelerate Clinical Trials for COVID-19 Patients in Need – P&T Community

WASHINGTON, June 3, 2020 /PRNewswire/ --A new systematic review and meta-analysis of clinical studies using mesenchymal stromal cells (MSCs) led by a team at the Mayo Clinic, and including researchers from Emory, Duke, Case-Western, and the University of Miami, shows a trend toward improved outcomes and reduced mortality for patients with acute respiratory distress syndrome (ARDS), a major complication for patients with COVID-19. This studyand several othersalso have shown that MSCs are safe for patients.

Based on these findings, the authors call for the rapid commencement of large-scale, confirmatory clinical trials to build on the existing evidence base, which shows a trend toward improved pulmonary function and reduced severe lung inflammation for patients with ARDS, paving the way toward another treatment option for seriously ill patients with COVID-19.

To date, nearly two million Americans have tested positive for COVID-19 and more than 100,000 Americans have died. In its most severe form, COVID-19 leads to ARDSa life-threatening lung injury that allows fluid to leak into the lungs and makes it difficult for patients to breathe. More than 40 percent of individuals hospitalized for severe and critical COVID-19 develop ARDS, and 22 percent to 62 percent of those who are diagnosed and become critically ill, die from the disease. There is no effective treatment for ARDS today; MSCs potentially offer a unique therapeutic option to help patients in need.

"The analysis shows a positive trend in outcomes when treating ARDS patients with MSC therapy and represents the potential to save thousands of patients with COVID-19 induced ARDS," said Wenchun Qu, MD, PhD of the Mayo Clinic and first author of the paper. "The potential benefitcombined with the demonstrated safety of these therapiessupports the need for rapid commencement of more clinical trials."

"Acute respiratory distress syndrome is a rapidly progressive disease that can occur in critically ill patients," said Anthony Atala, MD, Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "Having additional potential therapies, such as MSCs, could be highly beneficial to patients with COVID-19."

To date, the FDA has approved more than a dozen investigational new drug applications for the use of MSCs for COVID-19-related conditions. The National Institutes of Health (NIH) has also supported the use of MSCs and other regenerative cell therapies to help patients with other conditions. The bipartisan 21st Century Cures Act provided $30 million in funding to the NIH over three years for clinical research for such therapies. However, these limited investments expire in fiscal year 2020.

The Alliance for Cell Therapy Now and the Regenerative Medicine Foundation support the recommendation of the authors, who urge funding for larger studies that build on the results to date. Collaboration and funding are also needed to collect and analyze the evidence from multiple ongoing and new studies, to better evaluate outcomes and potential benefits of MSC therapy for COVID-19 patients in need. A portion of the more than $10 billion in funding directed by Congress to the Biomedical Advanced Research and Development Authority (BARDA) and the NIH for COVID-19 should be used to support these goals.

About the Alliance for Cell Therapy Now

Alliance for Cell Therapy Now (ACT Now) is an independent, non-profit organization devoted to advancing the availability of and access to safe and effective cell therapies for patients in need. ACT Now convenes experts and stakeholders to develop and advance sound policies that will improve the development, manufacturing, delivery, and improvement of regenerative cell therapies. See http://allianceforcelltherapynow.org/

About the Regenerative Medicine Foundation

The non-profit Regenerative Medicine Foundation (RMF) fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honoring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives. STEM CELLS Translational Medicine is RMF's official journal partner. See https://www.regmedfoundation.org/

View original content:http://www.prnewswire.com/news-releases/msc-therapy-for-acute-respiratory-distress-syndrome-its-time-to-accelerate-clinical-trials-for-covid-19-patients-in-need-301070329.html

SOURCE Alliance for Cell Therapy Now

Read more:
MSC Therapy for Acute Respiratory Distress Syndrome; It's Time to Accelerate Clinical Trials for COVID-19 Patients in Need - P&T Community

Using big data approaches to develop cell therapies – Drug Target Review

An area where stem cell biology and medicine are combining effectively is the establishment of new cell therapies. However, current therapies are limited to a narrow set of cell types that can be isolated or created and expanded in vitro. Dr Owen Rackham discusses how utilising computational approaches will further enhance applications of stem-cell-derived therapies in the future.

For decades (or perhaps centuries) the approach in cell biology has remained relatively unchanged. We isolate cells and with our confined knowledge of their endogenous conditions, begin to experiment until we can sustain them in vitro. Once established, we can conduct further investigation to assess a cells response to different conditions, changes over time or response to manipulation. This is especially true of stem cell biology, established from tireless efforts to incrementally improve culture conditions or differentiation protocols based on fragmented knowledge of developmental processes. Despite this, the promise of stem-cell therapies is already being realised in the clinic, but the breadth of cell types being used is still relatively narrow. Recent technological advances in the field have been focused on the safe and scalable manufacture of therapies. While these are revolutionary breakthroughs, the applications are largely limited to T cells, haematopoietic- and pluripotent-stem cells (HSCs and PSCs), a small fraction in the grand heterogeneity of cell types. Consequently, the lack of cell source diversity prevents cell therapy from fulfilling its clinical potential, pointing to the need for new means to isolate or generate source cells.

See the original post here:
Using big data approaches to develop cell therapies - Drug Target Review

Miracle cures and fast-track approval threatens medical advances, say scientists – The University of Manchester

Prof. Volker ter Meulen, Co-chair of the EASAC-FEAM Working Group and Past President of EASAC, said: Stem cell and gene-based therapies hold great medical promises. But we are alarmed over a trend to lower requirements of evidence. Also, we see an increasing problem of commercial clinics offering unregulated products and services

The Academies say the idea of regenerative medicine is to tackle diseases which up to now are incurable. According to the report, cosmetic applications, for example, are inappropriate for the time being.

So far, regenerative medicine has proven itself only in few specific clinical indications, for example for skin disorders. Yet, we see an increasing number of unregulated clinics promising a wide range of benefits on the basis of poorly characterised medicinal products with little evidence of effectiveness. They usually advertise their services via the internet with the primary intention of financial profit, explains EASAC Biosciences Programme Director Dr. Robin Fears.

The scientists urge the EU to resist the pressure and put patients first. When countries lower regulatory standards in their eagerness to support national economic interests, it is even more important for the EU as a major global player to defend the principles of international cooperation in health regulation, says Prof. George Griffin, Co-chair of the Working Group and President of FEAM.

We all want cures to be available in the shortest time frame possible. But our analysis and recommendations aim at ensuring that regulatory procedures are robust, transparent and evidence-based, concludes Cossu. Scientific research and proof are more important than ever. The EU and national regulators should be wary of not undermining public trust in science.

Read more:
Miracle cures and fast-track approval threatens medical advances, say scientists - The University of Manchester